RECURRENT TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for RECURRENT TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo shows promise for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests whether combining two targeted drugs—loncastuximab tesirine and mosunetuzumab—can shrink or eliminate tumors in people with diffuse large B-cell lymphoma that has returned or not responded to prior treatment. About 36 adults will receive the drug combination, and…
Matched conditions: RECURRENT TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New drug may boost CAR-T success in tough lymphomas
Disease control Recruiting nowThis study tests a drug called odronextamab given before CAR-T cell therapy for people with large B-cell lymphoma that has returned or not responded to treatment. The goal is to see if this approach can keep the cancer under control and help more patients successfully receive CAR…
Matched conditions: RECURRENT TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New drug combo aims to boost stem cell transplant success in hard-to-treat lymphoma
Disease control Recruiting nowThis study tests whether adding the drug epcoritamab to standard chemotherapy can improve outcomes for people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatment. About 43 adults will receive the combination before an autologous stem …
Matched conditions: RECURRENT TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 01, 2026 15:59 UTC